MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Guardant Health Inc

Suletud

SektorTervishoid

50.23 -2.09

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

49.46

Max

50.36

Põhinäitajad

By Trading Economics

Sissetulek

16M

-95M

Müük

1.7M

203M

Kasumimarginaal

-46.768

Töötajad

1,999

EBITDA

-12M

-111M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+20.7% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

333M

6.3B

Eelmine avamishind

52.32

Eelmine sulgemishind

50.23

Uudiste sentiment

By Acuity

50%

50%

131 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Guardant Health Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. juuli 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FCC Approves U.S. Cellular Sale to T-Mobile

11. juuli 2025, 17:28 UTC

Suurimad hinnamuutused turgudel

SharpLink Gaming Gains on Ethereum Purchase

11. juuli 2025, 16:57 UTC

Tulu

BASF Cuts Outlook on Global Economy Uncertainty

12. juuli 2025, 17:01 UTC

Tulu

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12. juuli 2025, 14:53 UTC

Tulu

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12. juuli 2025, 02:24 UTC

Omandamised, ülevõtmised, äriostud

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12. juuli 2025, 02:05 UTC

Omandamised, ülevõtmised, äriostud

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12. juuli 2025, 02:05 UTC

Omandamised, ülevõtmised, äriostud

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12. juuli 2025, 02:05 UTC

Omandamised, ülevõtmised, äriostud

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11. juuli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. juuli 2025, 19:46 UTC

Omandamised, ülevõtmised, äriostud

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. juuli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. juuli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. juuli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. juuli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. juuli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. juuli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. juuli 2025, 16:42 UTC

Tulu

BASF Cuts Outlook on Global Economic Uncertainty

11. juuli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. juuli 2025, 16:05 UTC

Tulu

BASF Will Publish Half-Year Results on July 30

11. juuli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. juuli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. juuli 2025, 16:03 UTC

Tulu

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. juuli 2025, 16:02 UTC

Tulu

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. juuli 2025, 16:01 UTC

Tulu

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. juuli 2025, 16:00 UTC

Tulu

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. juuli 2025, 15:59 UTC

Tulu

BASF Cuts 2025 Earnings View

11. juuli 2025, 15:58 UTC

Tulu

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. juuli 2025, 15:57 UTC

Tulu

BASF 2Q EBIT Before Special Items EUR810M

11. juuli 2025, 15:54 UTC

Tulu

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Võrdlus sarnastega

Hinnamuutus

Guardant Health Inc Prognoos

Hinnasiht

By TipRanks

20.7% tõus

12 kuu keskmine prognoos

Keskmine 60.65 USD  20.7%

Kõrge 70 USD

Madal 49 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Guardant Health Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

18

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

38.86 / 47.41Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

131 / 376 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.